Fluid Biomed Inc. announces world's first implantation of polymer-based neurovascular stent in human patients

Fluid Biomed Inc., a medical device company developing ReSolv™, the world's first hybrid polymer-metal flow-diverting stent to treat brain aneurysms, recently announced the international launch of REDIRECT, its first-in-human clinical trial. Phase 1 of this technical feasibility and safety study has begun with successful device implantation without adverse effect in human subjects at the pre-determined 30-day time point and recruitment is on-going.

FluidBiomed is an OBIO® member and presented at the OBIO® Investment Summit.